IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML

Acute myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric patients. Adoptive cell therapy by chimeric antigen receptor (CAR)-engineered T cells demonstrated a high therapeutic potential, but further development is required to ensure a safe and durable disease remis...

Descripción completa

Detalles Bibliográficos
Autores principales: Perriello, Vincenzo Maria, Rotiroti, Maria Caterina, Pisani, Ilaria, Galimberti, Stefania, Alberti, Gaia, Pianigiani, Giulia, Ciaurro, Valerio, Marra, Andrea, Sabino, Marcella, Tini, Valentina, Spinozzi, Giulio, Mezzasoma, Federica, Morena, Francesco, Martino, Sabata, Salerno, Domenico, Ashby, Julian François, Wingham, Brittany, Serafini, Marta, Martelli, Maria Paola, Falini, Brunangelo, Biondi, Andrea, Tettamanti, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300303/
https://www.ncbi.nlm.nih.gov/pubmed/36521101
http://dx.doi.org/10.1182/bloodadvances.2022008762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300303/
https://www.ncbi.nlm.nih.gov/pubmed/36521101
http://dx.doi.org/10.1182/bloodadvances.2022008762

Ejemplares similares